When Guidelines Outpace Capacity: A Systems Analysis of Genome-First Testing in Neurodevelopmental Disorders

Abstract Purpose Clinical guidelines now recommend exome or genome sequencing as first-line testing for autism spectrum disorder (ASD), intellectual disability (ID), and global developmental delay (GDD). However, the systems-level capacity needed to implement genome-first testing at scale remains poorly characterized. We quantified institutional demand for genomic testing among neurodevelopmental patients and compared it with available genetics clinic capacity. Methods We conducted a retrospective EHR review of all patients scheduled within a large Division of Developmental and Behavioral Pediatrics (DDBP) over four weeks (January 26–February 20, 2026). Patients were eligible if they had ASD, ID, and/or GDD and had not previously undergone exome or genome sequencing. We extracted demographics, prior genetic testing, and Social Deprivation Index (SDI) scores, and quantified available general and neurodevelopmental genetics clinic appointment slots during the same interval to assess workforce capacity. Results Of 473 eligible individuals, 72% were test-naïve. Most were male (72%) and Medicaid-insured (62%), with a mean SDI score of 54 (SD 26). Only 240 genetics clinic slots were available institution-wide during the same period, roughly half the eligible volume, revealing a substantial gap between guideline-recommended eligibility and specialist capacity. Conclusion At our institution, genome-first testing guidelines have outpaced existing genetics workforce capacity. These findings motivate an ongoing systems-redesign effort; alternative consent and testing-initiation workflows embedded within DDBP clinics may help bridge the evidence-to-practice gap and support equitable access to genomic medicine.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-13
DOI
https://doi.org/10.21203/rs.3.rs-10961999/v1
Primary Topic
Genomics and Rare Diseases
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

When Guidelines Outpace Capacity: A Systems Analysis of Genome-First Testing in Neurodevelopmental Disorders

Amelle Shillington, Rachel Doberstein, Cassandra Conrad, Jeremy Brown
4 links
Research Square
Genomics and Rare Diseases
preprint

When Guidelines Outpace Capacity: A Systems Analysis of Genome-First Testing in Neurodevelopmental Disorders

Amelle Shillington, Rachel Doberstein, Cassandra Conrad, Jeremy Brown
preprint en

Abstract

Abstract Purpose Clinical guidelines now recommend exome or genome sequencing as first-line testing for autism spectrum disorder (ASD), intellectual disability (ID), and global developmental delay (GDD). However, the systems-level capacity needed to implement genome-first testing at scale remains poorly characterized. We quantified institutional demand for genomic testing among neurodevelopmental patients and compared it with available genetics clinic capacity. Methods We conducted a retrospective EHR review of all patients scheduled within a large Division of Developmental and Behavioral Pediatrics (DDBP) over four weeks (January 26–February 20, 2026). Patients were eligible if they had ASD, ID, and/or GDD and had not previously undergone exome or genome sequencing. We extracted demographics, prior genetic testing, and Social Deprivation Index (SDI) scores, and quantified available general and neurodevelopmental genetics clinic appointment slots during the same interval to assess workforce capacity. Results Of 473 eligible individuals, 72% were test-naïve. Most were male (72%) and Medicaid-insured (62%), with a mean SDI score of 54 (SD 26). Only 240 genetics clinic slots were available institution-wide during the same period, roughly half the eligible volume, revealing a substantial gap between guideline-recommended eligibility and specialist capacity. Conclusion At our institution, genome-first testing guidelines have outpaced existing genetics workforce capacity. These findings motivate an ongoing systems-redesign effort; alternative consent and testing-initiation workflows embedded within DDBP clinics may help bridge the evidence-to-practice gap and support equitable access to genomic medicine.

Research Square
Cincinnati Children's Hospital Medical Center (US), University of Cincinnati (US)
Cincinnati Children's Hospital Medical Center, National Institutes of Health
Good health and well-being, Reduced inequalities
Genomics and Rare Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon